Sponsor hub

Washington University School of Medicine clinical trial failures

Review 185 stopped clinical trials from Washington University School of Medicine, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 14 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials185
Likely biological signals14
Shown below100

Dominant stop reasons

OPERATIONAL
94
OTHER/UNKNOWN
77
EFFICACY/FUTILITY
9
SAFETY
5

Notable sponsors

Washington University School of Medicine
185

Related phases

Phase II
74
Phase I
60
Phase IV
20
Unknown
19
Early Phase I
10

Crawlable stopped-trial records

Open Explore

Showing up to 100 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT06083571: Intranasal Ketorolac Trial

Phase II Headache, Migraine trial by Washington University School of Medicine. Stop reason: OPERATIONAL.

The eligibility criteria within the protocol led to the exclusion of a large proportion of potential participants, thereby limiting enrollment. During the conceptualization phase, the number of eligible patients was overestimated.

NCT03893318: IV Lidocaine in Pediatric AIS

Phase IV Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery trial by Washington University School of Medicine. Stop reason: OTHER/UNKNOWN.

PI moved to a different institution.

NCT06424236: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Phase II Alzheimers Disease trial by Washington University School of Medicine. Stop reason: OTHER/UNKNOWN.

DIAN-TU announced the discontinuation of the DIAN-TU-001 OLE based on the status of the drug program and findings from an interim efficacy analysis and.

NCT03395288: Nutraceutical Efficacy for rUTI

Phase II Urinary Tract Infections trial by Washington University School of Medicine. Stop reason: EFFICACY/FUTILITY.

Performed a futility analysis and determined that study objectives could not be met.

NCT03231397: Predictors of AAA Expansion and/or Rupture

Phase IV Abdominal Aortic Aneurysm (AAA) trial by Washington University School of Medicine. Stop reason: OPERATIONAL.

We were unable to recruit more subjects who met the inclusion/exclusion criteria and we have closed the study.